Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 222 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Norepinephrine Clear all
Recruiting No phase listed Observational

SUNOSI® (Solriamfetol) Pregnancy Registry

NCT06413420
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
Interventions
Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
Drug · Other
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
Female only
Enrollment
1,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Phase 3 Interventional

Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)

NCT07766655
View directory record Official record
Conditions
Smoking Cessation
Interventions
AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Phase 3 Interventional

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

NCT06413433
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Encino, California • Garden Grove, California • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 18, 2026, 8:02 PM EDT
Terminated Phase 4 Interventional Results available

Predicting, Understanding and Speeding Recovery After TKA

NCT02685735
View directory record Official record
Conditions
Pain, Total Knee Replacement, Total Hip Replacement
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 18, 2026, 8:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Norepinephrine in Emotional Processing

NCT00109642
View directory record Official record
Conditions
Psychopathy, Mental Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
20 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Not applicable Interventional

The GUARDIAN Trial

NCT04884802
View directory record Official record
Conditions
Blood Pressure
Interventions
Tight blood pressure management, Routine blood pressure management
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
45 Years and older
Enrollment
6,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Omaha, Nebraska • Wake Forest, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 18, 2026, 8:02 PM EDT
Completed No phase listed Observational Results available

Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis

NCT01001559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
Drug
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Phase 4 Interventional Results available

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

NCT02586623
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa capsules, Placebo capsules
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
168
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

NCT04144257
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[F-18]PBR06, [C-11]Methylreboxetine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Phase 4 Interventional

Treatment of Orthostatic Hypotension in SCI

NCT05839652
View directory record Official record
Conditions
Hypotension
Interventions
Midodrine Hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 18, 2026, 8:02 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Molecular Imaging of NET Using [C-11]MRB-PET in MS

NCT03207464
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[C-11]Methylreboxetine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Terminated No phase listed Observational

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

NCT05109195
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Standard of Care (SOC)
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Phase 4 Interventional

Major Depressive Disorder Study In Adults

NCT00049972
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
71
States / cities
Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Phase 1 Interventional

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

NCT02897063
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
Interventions
Droxidopa, Midodrine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 18, 2026, 8:02 PM EDT
Recruiting Phase 4 Interventional

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

NCT07322133
View directory record Official record
Conditions
Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
Interventions
Dopamine administration, Norepinephrine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 28 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Not yet recruiting Phase 4 Interventional

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

NCT06746753
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 8:02 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

NCT02558972
View directory record Official record
Conditions
Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting
Interventions
Northera (Droxidopa), Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Not applicable Interventional Results available

Optimal VAsopressor titraTION Pilot Randomized Controlled Trial

NCT01800877
View directory record Official record
Conditions
Hypotension, Shock
Interventions
Vasopressors
Drug
Lead sponsor
Francois Lamontagne
Other
Eligibility
17 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 18, 2026, 8:02 PM EDT
Completed Not applicable Interventional

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

NCT02495545
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
CSFD and elevation of MAP, Maintenance of MAP
Procedure
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 18, 2026, 8:02 PM EDT